Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Prep: Cook: Serves:

The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment.

INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people with Parkinson’s – is expected to be available in 2019.

Todd Sherer, CEO of The Michael J Fox Foundation, who funded early trials of the powder, said: “Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive.

“We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”

To read more on this topic click here.

For more information on Parkinson’s medication please visit the EPDA website.

Memory loss could be an indication of Parkinson’s

Last Month

Next Month

Go Back

Share this story

Comments

Recipes & Nutrition

Mouth-watering Michelin-starred meals for people with Parkinson’s

Delicious specialised recipes that meet your Parkinson's dietary needs

#UniteForParkinsons: the story so far

Highlights from #UniteForParkinsons 2017

Telemedicine: how Sweden is reducing waiting times for Parkinson’s treatment

Video calling tech is speeding up access to advanced treatment

Plant-based compounds could treat chronic pain in Parkinson’s, study finds

A six-year study has found that chronic pain in people with Parkinson’s is linked to a gene involved with how the brain responds to cannabis compounds. The investigation examined why some people with the condition experience persistent pain – and the impact it has on their work, daily life and social relationships. Conducted by researchers at Manchester’s Salford Royal Foundation Trust, UK, and funded by Parkinson’s UK, it is the largest study to investigate chronic pain in people with Parkinson’s. Dr Monty Silverdale, consultant neurologist at Greater Manchester Centre, said: “This study is significant because it shows the important role of genetics in chronic pain in Parkinson’s. “Our findings suggest that cannabis-based compounds may be worth investigating as a treatment for pain in Parkinson’s.”

Could playing table tennis help reduce Parkinson’s symptoms?

Researchers at Fukuoka University, Japan, have found that playing table tennis may help alleviate motor symptoms in Parkinson’s. As part of the study, 12 people with Parkinson’s with an average age of 73 played a five-hour session of table tennis every week for a period of six months. The sessions were developed specifically for people with the condition by experienced table tennis players from the university’s department of sports science. The participants were evaluated after three months and at the end of the study. At both evaluations, participants had reduced symptoms – showing improvement in speech, handwriting, walking and hand tremors. Two participants reported side-effects of backache and falling. Study author Ken-ichi Inoue, MD, of Fukuoka University said: “While this study is small, the results are encouraging because they show ping pong, a relatively inexpensive form of therapy, may improve some symptoms of Parkinson’s disease. A much larger study is…

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

Researchers have discovered that a molecule called BT13 could have potential to treat Parkinson’s. The study, conducted by scientists from the University of Helsinki, Finland, found that mice injected with the BT13 molecule had an increase in dopamine levels in the brain. Their findings also suggested that the molecule could lead to a new drug treatment to protect the brain cells that produce dopamine. Dopamine helps coordinate movement, but people with Parkinson’s have normally lost between 70 and 80% of the brain cells that produce the neurotransmitter when they are diagnosed with the condition. Professor David Dexter, Deputy Director of Research at Parkinson’s UK – which co-funded the study – said: “People with Parkinson’s desperately need a new treatment that can stop the condition in its tracks, instead of just masking the symptoms. “More research is needed to turn BT13 into a treatment to be tested in clinical trials, to…

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Recipes & Nutrition

Mouth-watering Michelin-starred meals for people with Parkinson’s

Global update

#UniteForParkinsons: the story so far

In my country

Telemedicine: how Sweden is reducing waiting times for Parkinson’s treatment

Plant-based compounds could treat chronic pain in Parkinson’s, study finds

Could playing table tennis help reduce Parkinson’s symptoms?

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

{title}

Subscribe

Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Recipes & Nutrition

Mouth-watering Michelin-starred meals for people with Parkinson’s

Global update

#UniteForParkinsons: the story so far

In my country

Telemedicine: how Sweden is reducing waiting times for Parkinson’s treatment

Plant-based compounds could treat chronic pain in Parkinson’s, study finds

Could playing table tennis help reduce Parkinson’s symptoms?

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

{title}

Subscribe

Sign in